Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

Tom van den Ende; Nicolien C. de Clercq; Mark I. van Berge Henegouwen; Suzanne S. Gisbertz; Elisabeth D. Geijsen; Rob H.A. Verhoeven; Sybren L. Meijer; Sandor Schokker; Mark P.G. Dings; Jacques Bergman; Nadia Haj Mohammad; Jelle P. Ruurda; Richard van Hillegersberg; Stella Mook; Max Nieuwdorp; Tanja D. de Gruijl; Tanya T.D. Soeratram; Bauke Ylstra; Nicole C.T. van Grieken; Maarten F. Bijlsma; Maarten C.C.M. Hulshof; Hanneke W.M. van Laarhoven

doi:10.1158/1078-0432.ccr-20-4443

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Combining nCRT with atezolizumab is feasible in patients with rEAC. On the basis of our exploratory biomarker study, future studies are necessary to elucidate the potential of neoadjuvant immunotherapy in patient subgroups.See related commentary by Catenacci, p. 3269.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ende et al. (2021) studied this question.

synapsesocial.com/papers/69ce19155c3278a7c310103f https://doi.org/10.1158/1078-0432.ccr-20-4443

View Full Paper

Ask AI

Bookmark

Share

Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

Ask about this paper

Abstract

Discussion

Cite This Study

Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading